IP Library Granted Patent US 7,601,493
Granted Patent B2
US 7,601,493 · App. 10/627,950 · Granted Oct 13, 2009

Methods and apparatus for screening and detecting multiple genetic mutations

Assignee: Nanogen, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,601,493
App. No.
10/627,950
Granted
Oct 13, 2009
Kind
B2
Abstract

An assay system and methods are described where patient samples containing genomic DNA are analyzed for the presence of known genetic polymorphisms using a universal reporter strategy. In a preferred embodiment, the amplified DNA is localized at test sites in an array of sites on a microchip followed by a series of hybridization reactions that screen for the presence of a single mutation from among a number of mutations, and allow the identification of specific mutations. In addition to universal reporters, the assay may use blockers and discriminators for screening and identification of known polymorphisms.

Claims (25)

1. A method for detecting a polymorphism related to a genetic disease in a patient sample nucleic acid, comprising the steps of:

providing the patient sample nucleic acid containing a first locus having a first polymorphism and a second locus having a second polymorphism on a site of a microarray, wherein the first or second polymorphism is related to the genetic disease;

providing an unlabeled blocker that is complementary to the first locus containing the first polymorphism;

hybridizing the unlabeled blocker with the first locus such that the first polymorphism is blocked by the unlabeled blocker and the second locus is unblocked;

providing a detectable discriminator that is capable of hybridizing with the second locus containing the second polymorphism and specifically identifying the second polymorphism;

hybridizing the detectable discriminator with the second locus containing the second polymorphism; and

detecting the second polymorphism by detecting the presence of the discriminator at the site of the microarray.

2. The method of claim 1 , wherein the site of the microarray comprises a site of an actively addressable electronic microarray.

3. The method of claim 2 , wherein the addressable electronic microarray includes a permeation layer.

4. The method of claim 2 , wherein the microarray further comprises multiple sites and multiple patient nucleic acid samples are provided on the multiple sites of the microarray.

5. The method of claim 1 , wherein the patient sample nucleic acid is amplified.

6. The method of claim 5 , wherein the amplification includes polymerase chain reaction (PCR).

7. The method of claim 5 , wherein the amplification includes ligase chain reaction (LCR).

8. The method of claim 5 , wherein the amplification includes strand displacement amplification (SDA).

9. The method of claim 5 , wherein the amplification is performed using transcription-based amplification system (TAS).

10. The method of claim 5 , wherein the amplification is performed using self-sustained sequence replication system (3 SR).

11. The method of claim 5 , wherein the amplification is performed using Qβ replicase amplification system (Qβ).

12. The method of claim 1 , further includes the step of performing a screening step for a number of patient nucleic acid samples.

13. The method of claim 1 , wherein the patient sample nucleic acid comprises multiple segments containing different loci.

14. The method of claim 13 , wherein the multiple segments containing different loci are affixed to an identical site of the microarray.

15. The method of claim 13 , wherein the multiple segments containing different loci are affixed to different sites of the microarray.

16. The method of claim 1 , further comprising the steps of:

providing a labeled amplification control that is capable of binding with the patient nucleic acid sample; and

hybridizing the labeled amplification control to the patient nucleic acid sample.

17. The method of claim 1 , wherein the genetic disease is cystic fibrosis.

Assignments (5)
ORDER RELEASING SECURITY AGREEMENTS AND AUTHORIZING ASSIGNMENT Recorded Jan 25, 2011
From: PORTSIDE GROWTH & OPPORTUNITY FUND
To: ELITECH HOLDING B.V.
Reel/Frame 025690/0537 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2010
From: ELITECH HOLDING B.V.
To: GAMIDA FOR LIFE B.V.
Reel/Frame 024069/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2009
From: NANOGEN, INC.; EPOCH BIOSCIENCES, INC.; NANOTRONICS, INC.
To: ELITECH HOLDING B.V.
Reel/Frame 023004/0585 →
GRANT OF SECURITY INTEREST Recorded Jul 25, 2008
From: NANOGEN, INC.
To: PORTSIDE GROWTH & OPPORTUNITY FUND, AS COLLATERAL AGENT
Reel/Frame 021291/0605 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2004
From: RADTKEY, RAY R.; HELD, LANCE C.; WALLACE, ROBERT BRUCE; MENGE, KAREN; CANTER, DAVID
To: NANOGEN, INC.
Reel/Frame 015002/0054 →
Continuity (3)
Provisional Application 6044398900 · Jan 30, 2003
Provisional Application 6039899200 · Jul 26, 2002
Related Publication 20040146880A1 · Jul 29, 2004